{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T01:08:57Z","timestamp":1711588137271},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"DOI":"10.7759\/cureus.57054","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T17:16:50Z","timestamp":1711559810000},"source":"Crossref","is-referenced-by-count":0,"title":["An Urticarial and Acral Manifestation of Bullous Pemphigoid After Vildagliptin Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Khushboo","family":"Bisht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surajbala","family":"Khuraijam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Theresa Sony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13100","article-title":"Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis","volume":"61","author":"Phan K","year":"2020","unstructured":"Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis. Australas J Dermatol. 2020, 61:e15-21. 10.1111\/ajd.13100","journal-title":"Australas J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2019.1619233","article-title":"Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics","volume":"42","author":"Nishie W","year":"2019","unstructured":"Nishie W. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics. Immunol Med. 2019, 42:22-8. 10.1080\/25785826.2019.1619233","journal-title":"Immunol Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto D","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. 2019, 94:133-46. 10.1590\/abd1806-4841.20199007","journal-title":"An Bras Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors","volume":"10","author":"Moro F","year":"2020","unstructured":"Moro F, Fania L, Sinagra JL, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020, 10:1432. 10.3390\/biom10101432","journal-title":"Biomolecules"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02272-x","article-title":"Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials","volume":"69","author":"Silverii GA","year":"2020","unstructured":"Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine. 2020, 69:504-7. 10.1007\/s12020-020-02272-x","journal-title":"Endocrine"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid","volume":"100","author":"Verheyden MJ","year":"2020","unstructured":"Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020, 100:adv00224. 10.2340\/00015555-3457","journal-title":"Acta Derm Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000443330","article-title":"Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors - one due to linagliptin","volume":"232","author":"Mendon\u00e7a FM","year":"2016","unstructured":"Mendon\u00e7a FM, Mart\u00edn-Gutierrez FJ, R\u00edos-Mart\u00edn JJ, Camacho-Martinez F. Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors - one due to linagliptin. Dermatology. 2016, 232:249-53. 10.1159\/000443330","journal-title":"Dermatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211022722","article-title":"Analysis of the clinical characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid","volume":"56","author":"Sun L","year":"2022","unstructured":"Sun L, Wang C, Wu C, Zhou Y, Wang C. Analysis of the clinical characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid. Ann Pharmacother. 2022, 56:205-12. 10.1177\/10600280211022722","journal-title":"Ann Pharmacother"},{"key":"ref9","article-title":"Vildagliptin-induced bullous pemphigoid","volume":"134","author":"Zhang AY","year":"2021","unstructured":"Zhang AY, Jarrett P. Vildagliptin-induced bullous pemphigoid. N Z Med J. 2021, 134:95-7.","journal-title":"N Z Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis K","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012, 26:249-53. 10.1111\/j.1468-3083.2011.04062.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03192-8","article-title":"Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin","volume":"19","author":"Chouchane K","year":"2021","unstructured":"Chouchane K, Di Zenzo G, Pitocco D, Calabrese L, De Simone C. Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. J Transl Med. 2021, 19:520. 10.1186\/s12967-021-03192-8","journal-title":"J Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.20.06562-1","article-title":"Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"156","author":"Bellinato F","year":"2021","unstructured":"Bellinato F, Maurelli M, Schena D, Gisondi P, Girolomoni G. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Ital J Dermatol Venerol. 2021, 156:455-9. 10.23736\/S2784-8671.20.06562-1","journal-title":"Ital J Dermatol Venerol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: Estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin K","year":"2018","unstructured":"Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: Estimating the risk of the new agents and characterizing the patients. JAMA Dermatol. 2018, 154:1152-8. 10.1001\/jamadermatol.2018.2352","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/235918-an-urticarial-and-acral-manifestation-of-bullous-pemphigoid-after-vildagliptin-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T17:16:53Z","timestamp":1711559813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/235918-an-urticarial-and-acral-manifestation-of-bullous-pemphigoid-after-vildagliptin-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.57054","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]}}}